Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Bioadaptives (BDPT) EBIAT (2019 - 2025)

Bioadaptives' EBIAT history spans 7 years, with the latest figure at -$823346.0 for Q4 2025.

  • Quarterly results put EBIAT at -$823346.0 for Q4 2025, down 121.46% from a year ago — trailing twelve months through Dec 2025 was -$1.6 million (down 73.26% YoY), and the annual figure for FY2025 was -$1.6 million, down 73.26%.
  • EBIAT for Q4 2025 was -$823346.0 at Bioadaptives, down from -$379502.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$13061.0 in Q3 2023 to a low of -$823346.0 in Q4 2025.
  • The 5-year median for EBIAT is -$246069.0 (2022), against an average of -$255752.2.
  • The sharpest move saw EBIAT skyrocketed 95.27% in 2023, then crashed 908.0% in 2025.
  • Year by year, EBIAT stood at -$214283.0 in 2021, then surged by 86.8% to -$28277.0 in 2022, then crashed by 848.83% to -$268301.0 in 2023, then crashed by 38.57% to -$371788.0 in 2024, then plummeted by 121.46% to -$823346.0 in 2025.
  • According to Business Quant data, EBIAT over the past three periods came in at -$823346.0, -$379502.0, and -$157914.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.